Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 3/20 | 0.35 |
| ▸ | QDPR | P09417 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15443938 | 0.85 | KDM4E (0.37) | MAPT | |
| SCHEMBL6968880 | 0.81 | QDPR (0.44) | HTR2CGABRA1GABRG2GABRB3CHRM4 | |
| SCHEMBL14571704 | 0.76 | QDPR (0.41) | HTR2CPLGQDPR | |
| SCHEMBL5757274 | 0.72 | HTR1A (0.40) | HTR2CGABRA1GABRG2GABRB3CHRM4 | |
| SCHEMBL5758789 | 0.71 | HTR2C (0.49) | HTR2CSLC18A3SIGMAR1 | |
| SCHEMBL8818232 | 0.71 | HTR2C (0.49) | HTR2CGABRA1GABRG2GABRB3CHRM4 | |
| SCHEMBL6956559 | 0.69 | HTR2C (0.46) | HTR2CGABRA1GABRG2GABRB3CHRM4 | |
| SCHEMBL6989306 | 0.69 | HTR2C (0.46) | HTR2CGABRA1GABRB2 | |
| SCHEMBL5758221 | 0.68 | HTR2C (0.46) | HTR2CGABRA1GABRG2GABRB3 | |
| SCHEMBL5584924 | 0.68 | HTR2C (0.46) | HTR2CGABRA1GABRG2GABRB3SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| EP-1188747-B1 | PHENOXYPROPYLAMINE COMPOUNDS | MITSUBISHI PHARMA CORP (JP) | 2005-09-07 | — | — | EP | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | HTR2C 9/4885GABRA1 410/4885GABRG2 1689/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | HTR2C 9/4885GABRA1 410/4885GABRG2 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.